Author

M. Ruschig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Organism:mouse· 1

Frequent Co-Authors

F. Bertoglio· 3 shared K. Eschke· 3 shared L. Cicin-Sain· 3 shared M. Hust· 3 shared Y. Kim· 3 shared D. Meier· 2 shared E. V. Wenzel· 2 shared G. Roth· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Bertoglio

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants

K. Metzdorf, H. Jacobsen, Y. Kim, L. G. Teixeira Alves, U. Kulkarni, K. Eschke, M. Z. Chaudhry, M. Hoffmann, F. Bertoglio, M. Ruschig, M. Hust, M. C. Brdovcak, J. Materljan, M. Sustic, A. Krmpotic, , L. Cicin-Sain

A single dose of a recombinant murine CMV vaccine expressing SARS-CoV-2 spike protein provides long-lasting immunity against multiple variants in mice.

bioRxiv · Nov 25, 2022Immunology

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

F. Bertoglio, V. Fühner, M. Ruschig, P. A. Heine, L. Abasi, T. Klünemann, U. Rand, D. Meier, N. Langreder, S. Steinke, R. Ballmann, K.-T. Schneider, K. D. R. Roth, P. Kuhn, P. Riese, , M. Hust

The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.

Cell Reports · Jul 1, 2021Peer-reviewedBioengineering

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

F. Bertoglio, D. Meier, N. Langreder, S. Steinke, U. Rand, L. Simonelli, P. A. Heine, R. Ballmann, K.-T. Schneider, K. D. R. Roth, M. Ruschig, P. Riese, K. Eschke, Y. Kim, D. Schaeckermann, , M. Hust

The paper identifies potent SARS-CoV-2 neutralizing antibodies from pre-pandemic human donors that bind the RBD-ACE2 interface, showing high neutralization efficacy in vitro.

bioRxiv · Jun 5, 2020Biochemistry